Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1436-3305
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study ; volume:25 ; number:1 ; day:28 ; month:9 ; year:2021 ; pages:245-253 ; date:1.2022
Gastric cancer ; 25, Heft 1 (28.9.2021), 245-253, 1.2022
- Creator
-
Yamaguchi, Kensei
Boku, Narikazu
Muro, Kei
Yoshida, Kazuhiro
Baba, Hideo
Tanaka, Shinji
Akamatsu, Ayumi
Sano, Takeshi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10120-021-01244-y
- URN
-
urn:nbn:de:101:1-2022042300291686725074
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yamaguchi, Kensei
- Boku, Narikazu
- Muro, Kei
- Yoshida, Kazuhiro
- Baba, Hideo
- Tanaka, Shinji
- Akamatsu, Ayumi
- Sano, Takeshi
- SpringerLink (Online service)
Other Objects (12)
A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
Role of tight junction proteins in gastroesophageal reflux disease
Two decades of gastric and gastroesophageal junction cancer surgery
Li Fraumeni Syndrome predisposes to gastro-esophageal junction tumours
A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
Role of tight junction proteins in gastroesophageal reflux disease
Two decades of gastric and gastroesophageal junction cancer surgery
Li Fraumeni Syndrome predisposes to gastro-esophageal junction tumours
A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
Role of tight junction proteins in gastroesophageal reflux disease
Two decades of gastric and gastroesophageal junction cancer surgery